AP3531A - 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof - Google Patents
9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereofInfo
- Publication number
- AP3531A AP3531A AP2013006989A AP2013006989A AP3531A AP 3531 A AP3531 A AP 3531A AP 2013006989 A AP2013006989 A AP 2013006989A AP 2013006989 A AP2013006989 A AP 2013006989A AP 3531 A AP3531 A AP 3531A
- Authority
- AP
- ARIPO
- Prior art keywords
- undecan
- dimaleate
- quinazolin
- diaza
- chlor
- Prior art date
Links
- JPFLINXTDIKQQV-SPIKMXEPSA-N (z)-but-2-enedioic acid;9-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-1,4-diazaspiro[5.5]undecan-5-one Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=12C=C(OC3CCC4(CC3)C(NCCN4)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F JPFLINXTDIKQQV-SPIKMXEPSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152895 | 2011-02-01 | ||
| PCT/EP2012/051298 WO2012104206A1 (de) | 2011-02-01 | 2012-01-27 | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-chinazolin-6- yloxy]-1,4-diaza-spiro[5.5]undecan-5-on dimaleat, dessen verwendung als arzneimittel und dessen herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2013006989A0 AP2013006989A0 (en) | 2013-07-31 |
| AP3531A true AP3531A (en) | 2016-01-13 |
Family
ID=43896655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2013006989A AP3531A (en) | 2011-02-01 | 2012-01-27 | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8853225B2 (es) |
| EP (1) | EP2670736B1 (es) |
| JP (1) | JP2014504619A (es) |
| KR (1) | KR20140011330A (es) |
| CN (1) | CN103608336A (es) |
| AP (1) | AP3531A (es) |
| AR (1) | AR085056A1 (es) |
| AU (1) | AU2012213556A1 (es) |
| BR (1) | BR112013019416A2 (es) |
| CA (1) | CA2826193A1 (es) |
| CL (1) | CL2013002031A1 (es) |
| CO (1) | CO6781555A2 (es) |
| EA (1) | EA023573B1 (es) |
| EC (1) | ECSP13012847A (es) |
| GE (1) | GEP20156423B (es) |
| IL (1) | IL227534A0 (es) |
| MA (1) | MA34845B1 (es) |
| MX (1) | MX2013008870A (es) |
| PE (1) | PE20141012A1 (es) |
| PH (1) | PH12013501599A1 (es) |
| SG (1) | SG192216A1 (es) |
| TN (1) | TN2013000323A1 (es) |
| UY (1) | UY33889A (es) |
| WO (1) | WO2012104206A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289881A1 (de) | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
| AP3531A (en) | 2011-02-01 | 2016-01-13 | Boehringer Ingelheim Int | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
| KR20140128318A (ko) | 2012-02-09 | 2014-11-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 1,4-보호된 9-하이드록시-5-옥소-1,4-디아자-스피로 [5.5] 운데칸의 입체선택적 합성 방법 |
| WO2014012859A1 (en) | 2012-07-19 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
| WO2015085654A1 (zh) * | 2013-12-12 | 2015-06-18 | 天津合美医药科技有限公司 | 喹唑啉衍生物 |
| CN105130913A (zh) * | 2015-08-25 | 2015-12-09 | 佛山市赛维斯医药科技有限公司 | 一类多取代的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
| CN105017164A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 含新型苯并喹唑啉和邻位氯结构的酪氨酸激酶抑制剂及用途 |
| CN109485648A (zh) * | 2018-12-17 | 2019-03-19 | 无锡合全药业有限公司 | 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法 |
| CN109608470A (zh) * | 2018-12-17 | 2019-04-12 | 上海药明康德新药开发有限公司 | 叔丁基-9-氧亚基-2,5,8-三氮杂螺[3.5]壬烷-2-甲酸基酯的合成方法 |
| CN109503579A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-9-甲酸基酯的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009098061A1 (de) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2010026029A1 (en) * | 2008-09-03 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Use of quinazoline derivatives for the treatment of viral diseases |
| EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| JP4776882B2 (ja) | 2002-03-30 | 2011-09-21 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法 |
| WO2006034015A1 (en) | 2004-09-17 | 2006-03-30 | Osi Pharmaceuticals, Inc. | (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
| JP2009518450A (ja) | 2005-12-12 | 2009-05-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法 |
| BRPI0818687A2 (pt) | 2007-10-26 | 2017-05-02 | Japan Tobacco Inc | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. |
| AP3531A (en) | 2011-02-01 | 2016-01-13 | Boehringer Ingelheim Int | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
-
2012
- 2012-01-27 AP AP2013006989A patent/AP3531A/xx active
- 2012-01-27 SG SG2013057880A patent/SG192216A1/en unknown
- 2012-01-27 BR BR112013019416A patent/BR112013019416A2/pt not_active IP Right Cessation
- 2012-01-27 PH PH1/2013/501599A patent/PH12013501599A1/en unknown
- 2012-01-27 US US13/359,807 patent/US8853225B2/en active Active
- 2012-01-27 EP EP12702480.0A patent/EP2670736B1/de active Active
- 2012-01-27 CN CN201280016804.XA patent/CN103608336A/zh active Pending
- 2012-01-27 EA EA201300872A patent/EA023573B1/ru not_active IP Right Cessation
- 2012-01-27 JP JP2013552160A patent/JP2014504619A/ja active Pending
- 2012-01-27 CA CA2826193A patent/CA2826193A1/en not_active Abandoned
- 2012-01-27 KR KR1020137023135A patent/KR20140011330A/ko not_active Withdrawn
- 2012-01-27 WO PCT/EP2012/051298 patent/WO2012104206A1/de not_active Ceased
- 2012-01-27 MX MX2013008870A patent/MX2013008870A/es not_active Application Discontinuation
- 2012-01-27 MA MA36143A patent/MA34845B1/fr unknown
- 2012-01-27 GE GEAP201213210A patent/GEP20156423B/en unknown
- 2012-01-27 PE PE2013001723A patent/PE20141012A1/es not_active Application Discontinuation
- 2012-01-27 AU AU2012213556A patent/AU2012213556A1/en not_active Abandoned
- 2012-01-31 AR ARP120100317A patent/AR085056A1/es unknown
- 2012-02-01 UY UY0001033889A patent/UY33889A/es unknown
-
2013
- 2013-07-12 CL CL2013002031A patent/CL2013002031A1/es unknown
- 2013-07-18 IL IL227534A patent/IL227534A0/en unknown
- 2013-07-29 TN TNP2013000323A patent/TN2013000323A1/fr unknown
- 2013-08-01 CO CO13183058A patent/CO6781555A2/es not_active Application Discontinuation
- 2013-08-21 EC ECSP13012847 patent/ECSP13012847A/es unknown
-
2014
- 2014-08-28 US US14/471,147 patent/US8906931B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009098061A1 (de) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2010026029A1 (en) * | 2008-09-03 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Use of quinazoline derivatives for the treatment of viral diseases |
| EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
Non-Patent Citations (1)
| Title |
|---|
| KUMAR L ET AL: "Salt selection in drug development", PHARMACEUTICAL TECHNOLOGY, ADVANSTAR COMMUNICATIONS,INC, US, Bd. 32, Nr. 3, 1. März 2008 (2008-03-01), Seiten 128-146, XP008127365, * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013008870A (es) | 2013-08-14 |
| BR112013019416A2 (pt) | 2019-09-24 |
| AU2012213556A1 (en) | 2013-08-22 |
| AR085056A1 (es) | 2013-08-07 |
| EA023573B1 (ru) | 2016-06-30 |
| CN103608336A (zh) | 2014-02-26 |
| US8906931B1 (en) | 2014-12-09 |
| KR20140011330A (ko) | 2014-01-28 |
| ECSP13012847A (es) | 2014-09-30 |
| JP2014504619A (ja) | 2014-02-24 |
| MA34845B1 (fr) | 2014-01-02 |
| IL227534A0 (en) | 2013-09-30 |
| AP2013006989A0 (en) | 2013-07-31 |
| CA2826193A1 (en) | 2012-08-09 |
| US20130030003A1 (en) | 2013-01-31 |
| SG192216A1 (en) | 2013-09-30 |
| US8853225B2 (en) | 2014-10-07 |
| PH12013501599A1 (en) | 2019-03-22 |
| EP2670736B1 (de) | 2017-03-15 |
| EP2670736A1 (de) | 2013-12-11 |
| EA201300872A1 (ru) | 2014-01-30 |
| NZ613917A (en) | 2015-08-28 |
| CO6781555A2 (es) | 2013-10-31 |
| WO2012104206A9 (de) | 2013-11-21 |
| GEP20156423B (en) | 2016-01-11 |
| US20140371226A1 (en) | 2014-12-18 |
| PE20141012A1 (es) | 2014-09-10 |
| UY33889A (es) | 2012-08-31 |
| WO2012104206A1 (de) | 2012-08-09 |
| CL2013002031A1 (es) | 2013-12-27 |
| TN2013000323A1 (en) | 2015-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3531A (en) | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| IL231386A0 (en) | Pyrazoloquinolinone derivatives, their preparation and medical use | |
| IL236898A0 (en) | 2, 3- benzodiazepines | |
| ZA201206630B (en) | Hetaryl-[1,8]naphthyridine derivatives | |
| ZA201407021B (en) | Novel thienopyrimidine derivatives,processes for the preparation thereof and therapeutic uses thereof | |
| WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
| IL232764A0 (en) | Fluoromethyl-6,5- - dihydro-1,34]-h]oxazine | |
| AP2014007670A0 (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | |
| ZA201404074B (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
| IL229567A0 (en) | Benzylidine-2h benzene [b] [4,1]thiazine-3(4h)-converted ones, their derivatives, and their medical uses | |
| EP2900678B8 (en) | Multimeric mannosides, a process for preparing the same and their uses as a drug | |
| SG11201404234YA (en) | Triazolo[4,5-d]pyrimidine derivatives | |
| IL232717A0 (en) | 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives | |
| ZA201401710B (en) | "new administration regime for n-hydroxy-4-{-3-(n,n-dimethylamethyl)benzofurun-2 ylcarbonylamino]ethoxy}benzaminde" | |
| IL239146A0 (en) | Aminocyclobutane derivatives, methods for their preparation and their use as drugs | |
| PT2870145T (pt) | Derivados de indeno, sua preparação e utilização como medicamentos | |
| PL2723742T3 (pl) | Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i zastosowanie | |
| PL2850070T3 (pl) | Pochodne benzo[1,3]dioksyny i ich zastosowanie jako antagonistów LPAR5 | |
| PL391832A1 (pl) | Sole N-triazynyloamoniowe, sposób ich wytwarzania oraz ich zastosowanie | |
| বণিক বার্তা | উচ্চশিক্ষার সংকট দূর করছে বেসরকারি বিশ্ববিদ্যালয় অধ্যাপক ড. আইনুন নিশাত উপাচার্য, ব্র্যাক বিশ্ববিদ্যালয় | |
| PL398413A1 (pl) | Zastosowanie kwasu fenylo-1,4-diaminobis(metylidenobisfosfonowego) do wytwarzania preparatu farmaceutycznego | |
| HK1195303A (en) | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | |
| PL398409A1 (pl) | Zastosowanie kwasów bifenylo-4,4'-diaminobis(metylidenobisfosfonowych) do wytwarzania preparatu farmaceutycznego |